What is Phenylketonuria?
PKU, also called phenylalanine hydroxylase deficiency, is the most common inborn error of amino acid metabolism. It is a recessive hereditary defect: the body cannot metabolize the essential amino acid phenylalanine, so it accumulates in blood and tissues and, untreated, causes severe intellectual disability in most affected children. Classic PKU is generally defined as untreated plasma phenylalanine exceeding 20 mg/dL (1200 µmol/L). Individuals with classic PKU almost always have intellectual disability unless levels are controlled by diet or pharmacologic treatment. In the United States and many countries, PKU is detected by newborn screening, and appropriately treated patients (low-phenylalanine diet, tetrahydrobiopterin, or both) can have normal intelligence.
Pathophysiology
Classic PKU is a deficiency of PAH that drives plasma phenylalanine up (>1200 µmol/L; reference range 35-90 µmol/L) and produces urinary phenyl pyruvic acid (approximately 1 g/d) and phenylacetic acid. PAH catalyzes the conversion of L-phenylalanine to L-tyrosine, the rate-limiting step in phenylalanine's oxidative degradation. PAH crystallizes as a tetramer, each monomer holding a catalytic domain and a tetramerization domain, and some of the most frequent PKU mutations sit at the interface of those two domains.
A small percentage of children with elevated phenylalanine have normal PAH but a defect in synthesizing or recycling BH4. This is sometimes called malignant PKU and can stem from biallelic mutations in the GCH1, PCB1, PTS, or QDPR genes. BH4 cofactor deficiency carries additional neurologic problems that dietary phenylalanine reduction alone will not fully correct, so these patients often need further treatments that may still fall short.
Statistics and Incidences
Frequency varies sharply by population. In the United States, classic PKU affects roughly 1 in 10,000 to 1 in 25,000 newborns, and newborn screening is mandatory in all states, which has effectively eliminated PKU as a cause of intellectual disability when treatment starts early (NICHD/NIH; USPSTF). About 0.04 to 1% of residents in intellectual disability clinics are affected. Incidence is low in African Americans (1/50,000) and high in Turkey (about 1 case in 2600 births), the Yemenite Jewish population (1/5300), Scotland (1:5300), Estonia (1:8090), Hungary (1/11,000), Denmark (1/12,000), France (1/13,500), the United Kingdom (1/14,300), Norway (1/14,500), China (1/17,000), Italy (1/17,000), Canada (1/20,000), Minas Gerais State in Brazil (1/20,000), and the former Yugoslavia (1/25,042). It is low in Finland (<1/100,000) and Japan (1/125,000). Newborn screening makes the neonate the usual point of diagnosis. In the United States PKU is most common in whites; worldwide, in whites and Asians. Women with PKU must restrict phenylalanine during pregnancy, because untreated maternal PKU can cause maternal PKU syndrome with congenital heart defects, brain malformations, microcephaly, and intellectual impairment in the infant.
Clinical Manifestations
Most infants with PKU appear normal at birth. The most characteristic finding is fair skin and hair from impaired melanin synthesis, which can be striking in black and Japanese patients, though not all untreated patients are fair and treated patients often have typical pigmentation. Eczema is common, particularly in the perineal area. Severe, progressive intellectual disability is characteristic. The urine carries a musty smell. Convulsions may occur, and untreated PKU can show eye hypopigmentation.
Assessment and Diagnostic Findings
Most states require a newborn blood test for phenylalanine level. The Guthrie inhibition assay screens blood from a simple heel prick; it is most reliable after the newborn has ingested protein, and standard practice is to test on the second or third day of life. A qualified laboratory measures plasma phenylalanine and tyrosine, with standard amino acid analysis by ion exchange chromatography or tandem mass spectrometry. Urine tests (ferric chloride test) may be negative in the first month and are rarely used now. Cranial MRI may be indicated in older patients with poor dietary control who have motor or cognitive deficits, or behavioral, cognitive, or psychiatric concerns.
Medical Management
Treatment is dietary: restrict phenylalanine, often with tyrosine supplementation. Start a low-phenylalanine formula (Lofenalac, Phenyl-free) as soon as the condition is detected; best results come from starting before the newborn is 3 weeks of age. The diet is very restrictive, omitting bread, meat, fish, dairy, nuts, and legumes, and the child stays on it at least into early adulthood and possibly indefinitely. Supplement other essential amino acids through medical foods and follow vitamins, minerals, and micronutrients closely, since stringent phenylalanine restriction has caused deficiencies of iron, zinc, selenium, and other nutrients and essential amino acids. Aspartame must be avoided because phenylalanine is one of its primary components; it appears in many artificially sweetened foods and drinks and some vitamins and medicines. A 12-oz can of aspartame-sweetened diet drink contains approximately 105 mg of phenylalanine (25 to 50% of the usual daily intake).
Pharmacologic Management
Patients who refuse dietary treatment may benefit to some degree from large neutral amino acids. Some patients see a significant drop in plasma phenylalanine after sapropterin, a commercially available, FDA-approved form of the tetrahydrobiopterin (BH4) cofactor. An investigational enzyme therapy uses an injectable phenylalanine ammonium lyase, which can substitute for phenylalanine hydroxylase (PAH), aimed at patients who do not respond to BH4.
Nursing Management
Nursing Assessment
Take a nutritional history: at birth, determine whether the newborn has taken any formula that is not phenylalanine-free, so you know what to correct. Examine the newborn for any manifestations that signal a need for emergency care.
Nursing Diagnoses
Common diagnoses include imbalanced nutrition (less than body requirements) related to the restrictive diet; impaired skin integrity related to scratching the perineal area from eczema; risk for injury related to convulsions; anxiety related to the disorder and adverse reactions the infant may experience; altered thought processes related to poor intellectual abilities; and deficient caregiver knowledge of the disorder and the newborn's care.
Nursing Care Planning and Goals
The plan aims for a caregiver who meets the infant's nutritional needs and manages PKU competently, an infant free from injury, and skin that stays intact and free from infection.
Nursing Interventions
Teach family caregivers which foods to avoid once the infant takes solids, and that special formulas (Lofenalac, Phenyl-free) replace regular formula or breast milk. Offer emotional support after diagnosis so the family can cope with the shock, anxiety, and stress. Educate them on the disease process and how to help the child develop normally; with phenylalanine kept in the acceptable range, growth and development are not affected. Keep dietary advice consistent by making the child's dietitian the single source of that advice. For convulsions, teach caregivers how to handle the child with safety as the priority.
Evaluation
The plan is met when the caregiver provides appropriate nutrition and manages PKU competently, the infant stays free from injury, and skin integrity remains intact and free from infection.
Documentation Guidelines
Document individual findings (contributing factors, interactions, the nature of social exchanges, specifics of behavior), intake and output, cultural and religious beliefs and expectations, the plan of care, the teaching plan, responses to interventions and teaching, and attainment of or progress toward the desired outcomes.
Frequently Asked Questions
What is phenylketonuria in simple terms?
PKU is an inherited disorder where the body cannot break down phenylalanine, an amino acid found in protein and in the sweetener aspartame. Without treatment, phenylalanine builds to toxic levels and damages the developing brain. With a low-phenylalanine diet started early, intelligence and development stay normal.
How is PKU detected in newborns?
Through routine newborn screening, a heel-prick blood test taken in the first day or two of life and required in all US states (NICHD/NIH). The test is most accurate after the baby has taken protein feeds, so timing matters. A positive screen is confirmed with quantitative plasma phenylalanine and tyrosine measurement.
How common is PKU in the United States?
Classic PKU affects roughly 1 in 10,000 to 1 in 25,000 newborns in the United States, with the rate varying by ancestry (USPSTF; NICHD/NIH). It is most common in people of European ancestry and less common in African Americans.
What is the main treatment for PKU?
A lifelong low-phenylalanine diet built around special medical formulas, with tyrosine and micronutrient supplementation. Some patients also respond to sapropterin, an FDA-approved form of the BH4 cofactor that lowers blood phenylalanine. Starting treatment before about 3 weeks of age gives the best outcomes.
Why must people with PKU avoid aspartame?
Aspartame breaks down into phenylalanine, which a person with PKU cannot clear. It appears in many diet drinks, sugar-free foods, and some medicines, so label-reading is part of daily management. A single 12-oz aspartame-sweetened diet drink can supply 25 to 50% of a day's allowable phenylalanine.
Can a woman with PKU have a healthy baby?
Yes, but she must tightly control phenylalanine before conception and throughout pregnancy. Uncontrolled maternal PKU can cause maternal PKU syndrome in the infant, including congenital heart defects, microcephaly, and intellectual impairment, even when the baby does not have PKU.